SANKYO/PARKE-DAVIS TROGLITAZONE POST-APPROVAL INTERACTION STUDIES URGED; NARROW, TYPE II DIABETES INDICATION WINS UNANIMOUS APPROVAL RECOMMENDATION
Studies assessing the interaction of Sankyo/Parke-Davis' Rezulin (troglitazone) diabetes treatment with other drugs should be performed following approval, Committee Chairman Henry Bone, MD, Henry Ford Hospital (Detroit), said during FDA's Endocrinologic & Metabolic Drugs Advisory Committee meeting Dec. 11.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth